Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Cash & Current Investments: 2022-2024

Historic Cash & Current Investments for Axsome Therapeutics (AXSM) over the last 3 years, with Dec 2024 value amounting to $315.4 million.

  • Axsome Therapeutics' Cash & Current Investments fell 0.62% to $325.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year decrease of 8.53%. This contributed to the annual value of $315.4 million for FY2024, which is 18.34% down from last year.
  • As of FY2024, Axsome Therapeutics' Cash & Current Investments stood at $315.4 million, which was down 18.34% from $386.2 million recorded in FY2023.
  • Axsome Therapeutics' Cash & Current Investments' 5-year high stood at $386.2 million during FY2023, with a 5-year trough of $200.8 million in FY2022.
  • For the 3-year period, Axsome Therapeutics' Cash & Current Investments averaged around $300.8 million, with its median value being $315.4 million (2024).
  • Per our database at Business Quant, Axsome Therapeutics' Cash & Current Investments soared by 92.29% in 2023 and then dropped by 18.34% in 2024.
  • Axsome Therapeutics' Cash & Current Investments (Yearly) stood at $200.8 million in 2022, then skyrocketed by 92.29% to $386.2 million in 2023, then fell by 18.34% to $315.4 million in 2024.